Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

MD2-TLR4-IN-1 mitigates synuclein preformed fibril-mediated inflammatory response in microglia: insights from an in vitro and in vivo study.

Created on 11 Nov 2026

Authors

Gurpreet Singh, Aman Dalal, Nitin Pal Kalia

Published in

Immunopharmacology and immunotoxicology. Pages 1-13. Nov 10, 2026. Epub Nov 10, 2026.

Abstract

Neuroinflammation is a key pathological feature of neurodegenerative diseases, including Parkinson's disease (PD), where α-synuclein activates microglia via TLRs, leading to inflammatory cytokine release and neuronal damage. In this study, we evaluated the therapeutic potential of MD2-TLR4-IN-1 against α-Syn PFF-induced neuroinflammation in N9 microglial cells and a mouse model.
The anti-neuroinflammatory and therapeutic effects of MD2-TLR4-IN-1 were evaluated using in vitro and in vivo models. In vitro studies in N9 microglial and SH-SY5Y neuronal cells included cytotoxicity assessment, Western blotting, and ELISA to analyze pro-inflammatory cytokines and microglial markers. In vivo, α-synuclein PFF-induced mice were assessed for locomotor and motor functions, along with biochemical and immunofluorescence analyses to evaluate tyrosine hydroxylase, α-synuclein, and TLR4 signaling proteins.
In vitro studies demonstrated that MD2-TLR4-IN-1 was non-cytotoxic in neuronal cells and significantly modulates M1and M2 microglia -associated markers. In vivo, treatment did not produce statistically significant changes in motor and locomotor activity but significantly downregulated α-synuclein PFF-induced activation of the TLR4 signaling pathway. Additionally, TH expression was nonsignificant in the treatment groups compared with the disease group.
MD2-TLR4-IN-1 effectively modulate TLR4 signaling in α-synuclein PFF-induced neuroinflammation. Both in vitro and in vivo findings demonstrate its anti-neuroinflammatory activity and its ability to modulate α-synuclein-associated inflammatory pathology, highlighting its potential as a candidate anti-neuroinflammatory agent for PD.

PMID:
43008111
Bibliographic data and abstract were imported from PubMed on 11 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 11
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement